Notice of the 10th Annual General Meeting 2026
Dear Shareholders,
We would like to express our gratitude for your continued interest and unwavering support. It is thanks to your encouragement that we have been able to take significant steps forward in our challenging mission to develop innovative new medicines.
Our upcoming Annual General Meeting (AGM) is a meaningful opportunity for us to share our achievements over the past year and discuss our vision for a brighter future. We cordially invite you to attend, share your valuable insights, and witness the continued growth of Orum Therapeutics.
📅 Meeting Details (AGM & Webcast Access Info)
Date & Time: March 27, 2026, at 9:00 AM KST
Eligibility: Shareholder as of Dec 31st, 2025
Location: 3/F Conference Hall, Exhibition Center 1, DCC Daejeon Convention Center, 107 Expo-ro, Yuseong-gu, Daejeon, South Korea
Requirements: Valid photo ID
Webcast Application Period: March 23 9AM KST to March 26 4PM KST
Key Agenda:
Approval of the 10th Term Financial Statements
Appointment of Outside Directors
Online Participation
For shareholders who are unable to attend in person, we have arranged for real-time online participation. Please note that online voting will not be available for those joining via the webcast
Webcast: Register Here
Please contact IR for further assistance (ir@orumrx.com)
Important Notice:
· Attendance at the online General Meeting of Shareholders is not recognized as attendance at the General Meeting of Shareholders under the Commercial Act, nor are voting rights or the right to speak granted.
· This live broadcast is provided exclusively to the shareholder and viewing rights cannot be transferred to a third party.
· Screen capturing, recording, filming, reproduction, and external posting or distribution without the Company's consent are prohibited.
J.P. Morgan Healthcare Conference
Event Details
Date: January 12–15, 2026
Location: San Francisco, California, USA
Corporate Day Hosted by Mirae Asset
Event Details
Date & Time: November 25, 2025 , 13:30 pm - 16:30 pm KST
Location: 56 Gukjegeumyung-ro, Yeouido-dong, Seoul
UBS Global Healthcare Conference
Event Details
Date: November 9-12, 2025
Location: Palm Beach, Florida, USA
2025 Extraordinary General Meeting
Event Details
The 2025 Extraordinary General Meeting took place on Friday, Aug 1, 2025 at 9AM KST at the Daejeon Convention Center, 3FL conference Hall, 107 Expo-ro, Yuseong-gu, Daejeon, South Korea
Proposal Reference Material ( KR / EN )
Outcomes : KR / EN
A total of 9,268,387 shares were represented in person or by proxy at the Company's Extraordinary General Meeting of Shareholders: the representation rate was 43.99% based on the total shares outstanding and entitled to vote held by persons other than the Principal Shareholder and its Affiliates
Proposal No. 1 : Election of directors
Proposal 1-1 : Election of Executive Director Lee Sung Joo | Approved
Proposal 1-2 : Election of Non-Executive Director Peter Unnam Park | Approved
Proposal No. 2 : Approval of Capital Reserve Reduction | Approved
Proposal No. 3 : Approval of Stock Option Grant | Approved
Proposal No. 4 : Approval of Amendment to the Articles of Incorporation | Approved
NDR (Non-Deal Roadshow) Hosted by Samsung Securities
Event Details
Title: NDR (Non-Deal Roadshow) Hosted by Samsung Securities
Date and Time: Monday, 2 June 2025 - Wednesday, 4 June 2025
UBS Asian Investment Conference 2025
Event Details
Title: UBS Asian Investment Conference 2025
Date and Time: Thursday, 29 May 2025
Samsung Global Investors Conference 2025
Event Details
Title: Samsung Global Investors Conference 2025
Date and Time: Thursday, 15 May 2025
2025 9th Annual General Meeting
Event Details
The 2025 9th Annual General Meeting took place on Friday, March 28, 2025 at 9AM KST at the Daejeon Convention Center, 3FL conference Hall, 107 Expo-ro, Yuseong-gu, Daejeon, South Korea
Presentation
Proposal Reference Material ( KR / EN )
Annual Report
Outcomes : KR / EN
A total of 12,106,876 shares were represented in person or by proxy at the Company's 9th Annual Meeting of Shareholders: the representation rate was 65.69% based on the total shares outstanding and entitled to vote held by persons other than the Principal Shareholder and its Affiliates
Proposal No. 1 : Approval of the FY2024 Financial Statements | Approved
Proposal No. 2 : Approval of Director Remuneration Limit | Approved
Proposal No. 3 : Approval of Auditor Renumeration Limit | Approved
Proposal No. 4 : Approval of Amendments to the Articles of Incorporation | Approved
2024 Annual Result Conference Call
Event Details
Title: 2024 Annual Result Conference Call
Date and Time: Wednesday, 26 March 2025
Orum Therapeutics to Host Fourth Quarter 2024 Earnings Conference Call
Event Details
Title Orum Therapeutics to Host Fourth Quarter 2024 Earnings Conference Call
Date and Time 3/28/25 9:00 KST, 3/27/25 20:00 EST(TBD)
Please click here if you would like to attend this meeting
UBS Asia Healthcare Corporate Day - Hong Kong 2024
Event Details
Title: UBS Asia Healthcare Corporate Day - Hong Kong 2024
Date and Time: Thursday, 28 - Friday, 29 November 2024
Orum Therapeutics to Hold Analyst Day in Korea
Event Details
Title: Orum Therapeutics to Hold Analyst Day in Korea
Date and Time: 10/18/24, All day
Orum Therapeutics to Host a Global Media Conference Call for the IPO
Event Details
Title: Orum to Host a Global Media Conference Call for the IPO
Date and Time: 10/7/24 10:00 KST, 10/6/24 20:00 EST
Orum Therapeutics Announces Three Presentations At AACR 2023
Poster Title:
PD-1-Cbl-bi TPS² preclinical poster
A novel antibody-enabled Dual-precision Targeted Protein Stabilization (TPS²) that augments anti-tumor immune response by targeting Cbl-b inhibitor to exhausted T cells while blocking checkpoint molecule, PD-1
ORM-6151: A first-in-class CD33-antibody enabled GSPT1 degrader for AML
ORM-5029 predictive biomarker poster
Development of RNAscope multiplex-based assay for exploratory pharmacodynamic biomarkers assessment in breast cancer patients from Phase I clinical trial of ORM-5029, a potent GSPT1 degrader
Date and Time: 4/17/2023, 9:00 AM - 12:30 PM ET
Orum Therapeutics Presents Positive Preclinical Data Of ORM-6151 at ASH 2022
Title: ORM-6151, A First-In-Class, CD33-GSPT1 Dual-Precision Targeted Protein Degrader For AML.
Date and Time: 12/10/22 5:30 PM to 7:30 PM CST
Orum Therapeutics Presents Positive Preclinical Data Of ORM-6151, A First-In-Class, CD33-GSPT1 Dual-Precision Targeted Protein Degrader For AML, At ASH 2022
Poster Title: ORM-6151: A First-in-Class, Anti-CD33 Antibody-Enabled GSPT1 Degrader for AML
Date and Time: 12/10/2022, 5:30 PM to 7:30 PM CST
Orum Therapeutics Presents Preclinical Data At AACR 2022 Highlighting Novel Dual-Precision Targeted Protein Degrader, ORM-5029, Degrading GSPT1
Date and Time: 4/13/2022, 9:00 AM to 12:30 PM ET